Previous 10 | Next 10 |
C ash of approximately $ 19.9 million as of March 31, 202 3 , provide s ample runway to fund operations into Q2 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and GTB-5550 , and initiate cl...
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE ®...
Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January 4, 2023. Cash on hand, coupled with significant recent cost redu...
2023-03-24 07:13:27 ET Summary Fate Therapeutics' recent Janssen debacle has brought out comparisons with Geron. However, let's not forget that Geron has never gone back to pre-2019 prices. Fate investors would do well when they rethink their strategy. Fate Therapeut...
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that Dr...
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...
Cancer-focused nano-cap biotech GT Biopharma ( NASDAQ: GTBP ) lost ~8% in the pre-market trading Friday after announcing a registered direct offering to sell 6.5M shares of its common stock and warrants to raise $6.5M in gross proceeds. The capital raise is part of an agreement th...
BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...
Clinical stage immuno-oncology company focused on developing innovative therapeutics, GT Biopharma ( NASDAQ: GTBP ) based on the company's proprietary natural killer (NK) cell engager, TriKE platform, has named Dr. Jeff Miller, renowned NK ell cancer specialist as consu...
BRISBANE, CALIFORNIA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engage...
News, Short Squeeze, Breakout and More Instantly...
GT Biopharma (NASDAQ:GTBP) shares rose Tuesday morning before pulling back and turning negative after the company announced a direct offering. The ...
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company’s common stock at a purcha...
GT Biopharma, Inc. (NASDAQ:GTBP) shares are racing higher Monday on heavy trading volume. Here's a look at what's going on. What To...